Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01076556 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

NIH

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage I Small Lymphocytic Lymphoma
Stage II Chronic Lymphocytic Leukemia
Stage II Small Lymphocytic Lymphoma
Stage III Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage IV Chronic Lymphocytic Leukemia
Stage IV Small Lymphocytic Lymphoma

Interventions

DRUG: Alvocidib Hydrochloride
DRUG: Cyclophosphamide
OTHER: Diagnostic Laboratory Biomarker Analysis
OTHER: Pharmacological Study
BIOLOGICAL: Rituximab

Sponsor

National Cancer Institute (NCI)